Second Study Affirms iMDx GraftAssure Superiority, Enabling First-Ever Transplant Rejection 'Rule-In' Option
Summary
Insight Molecular Diagnostics announced the publication of a second peer-reviewed study in Transplant International, affirming the superiority of its GraftAssure assay's proprietary dd-cfDNA Combination Model (CM)-score. The study demonstrated the CM-score's strong correlation with clinically significant transplant rejection indices, outperforming other measures. This follows previous positive data presented at the World Transplant Congress in 2025 and builds on the company's recent announcement of key milestones for the GraftAssure product, reinforcing its clinical differentiation. The study highlights the assay's ability to provide an "unprecedented" positive predictive value above 80%, enabling a "rule-in option for transplanted organ rejection for the first time." This is a significant clinical advancement that could capture substantial share in the $2 billion-plus addressable market for transplant rejection testing, materially impacting the company's revenue potential. Investors will be watching for further commercialization updates and regulatory progress as iMDx aims to deliver this diagnostic test kit for clinical use in 2026.
At the time of this announcement, IMDX was trading at $4.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.2M. The 52-week trading range was $2.33 to $8.51. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.